New England Journal of Medicine· 2016Q1· Clinical trial
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- 5,101citations
- Q1SCImago
- 2016year
Short summary
Nivolumab, an anti-PD-1 antibody, significantly improved overall survival in patients with recurrent head and neck squamous-cell carcinoma after platinum chemotherapy, offering a new standard of care.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Otorhinolaryngology
OtorhinolaryngologyMedicine